Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma

J. D. Bitran; R. K. Desser; T. R. DeMeester; M. Colman; R. Evans; A. Billings; M. Griem; L. Rubenstein; C. Shapiro; H. M. Golomb

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma

J. D. Bitran, R. K. Desser, T. R. DeMeester, M. Colman, R. Evans, A. Billings, M. Griem, L. Rubenstein, C. Shapiro, H. M. Golomb

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Abstract

23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.

Original language	English (US)
Pages (from-to)	1225-1230
Number of pages	6
Journal	Unknown Journal
Volume	60
Issue number	9
State	Published - 1976
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{ca7b9eafc6bf482eb50b8963caec086d,

title = "Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma",

abstract = "23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.",

author = "Bitran, {J. D.} and Desser, {R. K.} and DeMeester, {T. R.} and M. Colman and R. Evans and A. Billings and M. Griem and L. Rubenstein and C. Shapiro and Golomb, {H. M.}",

year = "1976",

language = "English (US)",

volume = "60",

pages = "1225--1230",

journal = "Unknown Journal",

issn = "1574-7891",

publisher = "John Wiley and Sons Ltd",

number = "9",

}

TY - JOUR

T1 - Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma

AU - Bitran, J. D.

AU - Desser, R. K.

AU - DeMeester, T. R.

AU - Colman, M.

AU - Evans, R.

AU - Billings, A.

AU - Griem, M.

AU - Rubenstein, L.

AU - Shapiro, C.

AU - Golomb, H. M.

PY - 1976

Y1 - 1976

N2 - 23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.

AB - 23 patients with metastatic non oat cell bronchogenic carcinoma (MNOBC) were treated with cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) after radiation therapy. Objective responses were seen in 11 of 23 patients (48%) with a projected median survival time of 12.5 mth for responding patients and patients with stable disease. Lung, liver and cutaneous sites of involvement proved to be highly responsive; bone involvement was less responsive. CAMP is an effective combination in the treatment of MNOBC and its use in patients with less advanced disease should be explored.

UR - http://www.scopus.com/inward/record.url?scp=0017056306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017056306&partnerID=8YFLogxK

M3 - Article

C2 - 189920

AN - SCOPUS:0017056306

SN - 1574-7891

VL - 60

SP - 1225

EP - 1230

JO - Unknown Journal

JF - Unknown Journal

IS - 9

ER -

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) effective four drug combination chemotherapy for metastatic non oat cell bronchogenic carcinoma

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this